Analyst Comment AbbVie Parkinson’s drug ABBV-951 faces a few hurdles before FDA approval GlobalData Healthcare
Analyst Comment Rivaroxaban reduces adverse kidney events in atrial fibrillation patients with CKD GlobalData Healthcare
Analyst Comment First patients enrolled in Bayer’s Phase III trial for FXIa inhibitor asundexian GlobalData Healthcare
Analyst Comment TauRx’s HMTM could be the first anti-tau disease-modifying drug for Alzheimer’s GlobalData Healthcare
Features The great wall: why overseas sponsors are yet to fully tap into China’s clinical trial resources Reynald Castañeda and Andrew Hillman